Global Hospital Acquired Pneumonia Treatment Market Size & Growth Trends

According to FutureWise analysis the Hospital Acquired Pneumonia Treatment Market in 2025 is US$ 2.71 billion, and is expected to reach US$ 4.59 billion by 2033 at a CAGR of 6.81%. The market is expanding due to an increase in hospital-acquired infections and rising antibiotic resistance, which drive the need for effective treatments. The growing adoption of advanced therapeutic interventions and the launch of new antibiotics and supportive care therapies are expected to improve patient outcomes and create new market opportunities.

Hospital-acquired pneumonia (HAP) is a condition that occurs in patients after they have been admitted to the hospital for more than 48 hours. The public healthcare system faces a significant challenge due to HAP, as it is the second most common hospital-acquired infection. Pneumonia causes inflammation in the lungs, primarily affecting the alveoli, which are microscopic air sacs. The main causes of HAP are bacterial or viral infections, and it can be classified based on how the patient acquired the infection.

Pneumonia is a leading cause of death worldwide, with a fatality rate ranging from 4% to 10%. Among the different types of pneumonia, HAP is the most common. It has a severe impact on patients' lifestyles and is associated with a high mortality rate, necessitating immediate medical intervention. As a result, there is a significant demand for pharmacological treatments to manage the disease effectively. According to the Journal of Infectious Control and Epidemiology, the overall incidence of HAP in the U.S. is 1.6%, which translates to approximately 3.63 cases per 1,000 patients. The increasing prevalence of HAP in healthcare settings indicates potential market growth.

Moreover, the rising risk factors associated with longer hospital stays have prompted the development of standardized guidelines for effective management through pharmacological interventions. All these factors contribute to the potential growth of the HAP market.

FutureWise Market Research has published a report that provides an insightful analysis of Hospital Acquired Pneumonia Treatment Market trends that are affecting the overall market growth.

Request a Free Sample @ https://www.futurewiseresearch.com/contact.aspx?rpt=197&type=requestsample

Hospital Acquired Pneumonia Treatment Market Segmentation:

By Drug Type

• Tazobactam
• Cefepime
• Levofloxacin
• Imipenem
• Meropenem

By End User

• Hospitals
• Retail Pharmacies

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape in Hospital Acquired Pneumonia Treatment Market:

• Teva Pharmaceutical Industries
• Pfizer Inc
• Novartis Ag
• Mylan N.V.
• Allergan plc
• Sun Pharmaceuticals
• Fresenius Kabi
• Endo International

Recent developments by key players in Hospital Acquired Pneumonia Treatment Market:

Pfizer 

• In February 2025, the U.S. Food and Drug Administration (FDA) approved EMBLAVEO®, the first and only fixed-dose intravenous combination of aztreonam, a monobactam antibiotic, and avibactam, a β-lactamase inhibitor. This approval was based on positive results from the Phase 3 REVISIT and ASSEMBLE studies, which demonstrated the efficacy and safety of EMBLAVEO® in treating serious infections caused by Gram-negative bacteria, including hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP).
• Ceftobiprole, marketed as Zevtera or Mabelio, received FDA approval in April 2024 for the treatment of various serious infections, including hospital-acquired pneumonia (HAP), and it also addresses MRSA and resistant Gram-negative pathogens. This introduces a refreshed broad-spectrum option to the U.S. market.

Novartis

DFV890 is an oral NLRP3 inflammasome inhibitor developed by Novartis, which is currently undergoing Phase IIa clinical trials aimed at treating COVID-19 pneumonia and acute respiratory distress syndrome (ARDS). Although it is not specifically targeted at hospital-acquired pneumonia (HAP), DFV890 represents a novel host-directed anti-inflammatory approach that could provide therapeutic benefits in managing severe lung inflammation caused by hospitalization and the complications of secondary pneumonia.

Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=197&license=multi

**Objectives of this Study: **

1. To provide a comprehensive analysis of the Hospital Acquired Pneumonia Treatment Market By Drug Type, by End-User and By Region.
2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

                                                                                                                
Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
• The customization services offered are free of charge with the purchase of any license of the report.
• You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com

Article source: https://article-realm.com/article/Health-Fitness/78010-Global-Hospital-Acquired-Pneumonia-Treatment-Market-Size-and-Growth-Trends.html